CYTK · Cytokinetics, Incorporated

Cytokinetics completed a significant public offering of common stock, raising approximately $760.2 million in net proceeds. The offering consisted of 9,859,155 shares sold at $71.00 per share, with underwriters fully exercising an option for an additional 1,478,873 shares. The underwriting agreement includes standard representations, warranties, and indemnification provisions. The proceeds will provide substantial capital for the company's operations and strategic initiatives. The offering was conducted under an existing automatic shelf registration statement, indicating the company's preparedness for capital markets activities. This financing strengthens Cytokinetics' balance sheet and supports its ongoing development programs.